Aveanna Healthcare beats Q2 revenue estimates, raises annual guidance

Aveanna Healthcare Holdings

07/08/2025 11:39

Overview

Aveanna Healthcare Q2 revenue grows 16.8%, beating analyst expectations

Net income for Q2 rises 94.3% yr/yr

Co raises full-year 2025 revenue and adjusted EBITDA guidance

Outlook

Aveanna raises full-year 2025 revenue guidance to over $2.3 bln

Company increases full-year 2025 adjusted EBITDA guidance to over $270 mln

Aveanna cites strategic transformation as key driver for growth

Company sees continued positive momentum in all operating divisions

Result Drivers

PDS SEGMENT GROWTH - Revenue increase driven by $78.2 mln rise in PDS segment

ACQUISITION IMPACT - Thrive Skilled Pediatric Care acquisition expands pediatric services, aiding growth

GROSS MARGIN IMPROVEMENT - Gross margin rose to 35.8% from 31.3%, contributing to higher profitability

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$589.60 mln
$535.40 mln (8 Analysts)
Q2 EPS
$0.13
Q2 Net Income
$27 mln
Q2 Adjusted EBITDA
$88.40 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 5 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy."

Wall Street's median 12-month price target for Aveanna Healthcare Holdings Inc is $5.75, about 32.3% above its August 6 closing price of $3.89

The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 33 three months ago

Press Release: ID:nGNX63TMHZ

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)